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Abstract
Background
Mutations in the smooth endoplasmic reticulum (sER) calcium channel Inositol
Trisphosphate Receptor type 1 (IP3R1) in humans with the motor function coordination
disorders Spinocerebellar Ataxia Types 15 and 16 (SCA15/16) and in a corresponding mouse
model, the IP3R1delta18/delta18 mice, lead to reduced IP3R1 levels. We posit that increasing
IP3R1 sensitivity to IP3 in ataxias with reduced IP3R1 could restore normal calcium
response. On the other hand, in mouse models of the human polyglutamine (polyQ) ataxias,
SCA2, and SCA3, the primary finding appears to be hyperactive IP3R1-mediated calcium
release. It has been suggested that the polyQ SCA1 mice may also show hyperactive IP3R1.
Yet, SCA1 mice show downregulated gene expression of IP3R1, Homer, metabotropic
glutamate receptor (mGluR), smooth endoplasmic reticulum Ca-ATP-ase (SERCA),
calbindin, parvalbumin, and other calcium signaling proteins.

Results
We create a computational model of pathological alterations in calcium signaling in
cerebellar Purkinje neurons to investigate several forms of spinocerebellar ataxia associated
with changes in the abundance, sensitivity, or activity of the calcium channel IP3R1. We find
that increasing IP3R1 sensitivity to IP3 in computational models of SCA15/16 can restore
normal calcium response if IP3R1 abundance is not too low. The studied range in IP3R1
levels reflects variability found in human and mouse ataxic models. Further, the required fold
increases in sensitivity are within experimental ranges from experiments that use IP3R1
phosphorylation status to adjust its sensitivity to IP3. Results from our simulations of
polyglutamine SCAs suggest that downregulation of some calcium signaling proteins may be
partially compensatory. However, the downregulation of calcium buffer proteins observed in
the SCA1 mice may contribute to pathology. Finally, our model suggests that the calciumactivated voltage-gated potassium channels may provide an important link between calcium
metabolism and membrane potential in Purkinje cell function.

Conclusion
Thus, we have established an initial platform for computational evaluation and prediction of
ataxia pathophysiology. Specifically, the model has been used to investigate SCA15/16,
SCA1, SCA2, and SCA3. Results suggest that experimental studies treating mouse models of
any of these ataxias with appropriately chosen peptides resembling the C-terminal of IP3R1
could adjust receptor sensitivity, and thereby modulate calcium release and normalize IP3
response. In addition, the model supports the hypothesis of IP3R1 supersensitivity in SCA1.

Keywords
Model, IP3R, Homer, CAG repeat instability, KCa channels, Ataxia, Computational, BK
channel, Spinocerebellar, Virtual Cell

Background
Degeneration of the cerebellum or dysfunction of the Purkinje neurons leads to lack of motor
coordination, or ataxia, and impaired motor learning [1]. There are several forms of
hereditary ataxia, but the genetic basis of many ataxias is unknown. The IP3R1 calcium
channel has been implicated in ataxic mice [2-11] and very recently in humans with ataxia
[3,9,12-17](see reviews [18,19]). A portion of IP3R1 is represented in Figure 1a and, along
with Table 1, will be referenced in various sections of this computational study, which
focuses on a handful of ataxias involving this key calcium handling protein. Spinocerebellar
ataxia 15 (SCA15) and Spinocerebellar ataxia 16 (SCA16) are two forms of autosomal
dominant pure cerebellar ataxia that involve enormous heterozygous deletions or missense
mutations in IP3R1 [15-17] (see Figure 1b and Table 1). However, pathophysiology of
SCA15/16 has not been studied extensively. The ITPR1Δ18/wt and ITPR1Δ18/Δ18 mice (mouse
models for SCA15/16 [3]) possess heterozygous and homozygous, respectively, in-frame 18
bp deletions in exon 36 of the gene that encodes IP3R1. These mice showed reduced levels of
cerebellar IP3R1 on Western blot and with immunofluorescence [3] (Figure 1b). IP3R1+/−
mice also exhibit motor discoordination on the rotor rod test, and IP3R1−/− mice show lack of
balance when upright [2,5]. Various other forms of ataxia in mice and humans with causal
mutations in genes other than IP3R1 also show reduced IP3R1 protein levels [11,14,20].
Taken together, these findings suggest that haploinsufficiency of IP3R1 may contribute to
cerebellar ataxia [12].
Figure 1 Schematics relevant to this study. a, A portion of the regulatory domain of IP3R1
and the C-terminal, adapted from [21,22], with the PP1 binding motif and mutations for
ITPR118/18 and ITPR1op1/opt mice. b, Summary of various aspects of this study. IP3R1 is
the center of this study, involved in phosphoinositol signaling, calcium release, membrane
potential modulation; the dysregulation of any of these functions may lead to ataxia

Table 1 Ataxic mouse models relevant to this study
Ataxia model

Mutated gene
product

Protein name

BK -/-

BK

IP3R1 -/IP3R1 +/IP3R1
delta18/delta18
IP3R1 opt/opt
SCA15
SCA16
PMCA -/-

IP3R1
IP3R1
IP3R1

Large conductance calciumactivated voltage-gated
potassium channel
Inositol triphosphate receptor 1
Inositol triphosphate receptor 1
Inositol triphosphate receptor 1

IP3R1
IP3R1
IP3R1
PMCA

SCA1
SCA2
SCA3

Ataxin1
Ataxin2
Ataxin3

Inositol triphosphate receptor 1
Inositol triphosphate receptor 1
Inositol triphosphate receptor 1
Plasma Membrane Calcium
ATPase
Ataxin-1
Ataxin-2
Ataxin-3

Pathology

Compensation
*Observed/**Suggested
Therapeutic
Altered Precision
--Timing
No IP3R1
R
R

-S**
S**

R
R
R
No PCMA

Equivocal
S**
S**
R*

P,A,I
P,A,S,I
P,A,S,I

R*
R**
R*

P = Polyglutamine expansion; S = Supersensitive IP3R1; A = Association of mutant Ataxin
with IP3R1 C-terminal; R = Reduced IP3R1 abundance; I = Increased calcium release
The mechanism of pathology is different in polyglutamine ataxias. Humans with
spinocerebellar Ataxia 1 (SCA1), spinocerebellar ataxia 2 (SCA2), and spinocerebellar ataxia
3 (SCA3), and their corresponding mouse models, have large numbers of unstable
polyglutamine (polyQ, CAG) repeats in the Ataxin-1 [23,24], Ataxin-2 [25], and Ataxin-3
[26-28] proteins, respectively. All three mouse models show increased calcium release in
response to IP3, relative to wild type mice [6,8,10], with results from SCA2 and SCA3
suggesting a mechanism involving supersensitive IP3R1 [6,10,18]. SCA1 and SCA3 mice
have reduced expression of IP3R1 and other glutamatergic signaling proteins [29], in addition
to increased IP3R1-mediated calcium release, relative to wild type mice [8]. This paradox is
yet to be explained [30]. Gardner suggests that SCA15/16 in humans found to have actual
mutations in ITPR1, the gene that encodes the IP3R1 protein, be termed ITPR1-associated
ataxia [31]. However, we have termed a subset of ataxias, not just with reduced IP3R1 but
also with supersensitive IP3R1, and regardless of the mutated gene (e.g., ITPR1, Ataxin-1,
Ataxin-2, Ataxin-3) as ‘IP3R1-associated ataxias’ [32].
A prior modeling study by Hernjak et al. explores the significance of experimental
observations in normal cerebellar Purkinje neurons, which show markedly lower sensitivity
and higher abundance of IP3R1 relative to other cell types [33-35]. This is the opposite of
what is seen in SCA3 and suggested in SCA1. Hernjak et al. demonstrated that the normally
high levels of IP3R1 ensure robust calcium signals in an individual spine, and that the
normally low sensitivity of IP3R1 to IP3 confines the calcium transients to the stimulated
spine, without spillover to adjacent spines [35]. Thus, they argued that IP3R1 abundance and
sensitivity have independent effects on calcium signals and that changes in one do not appear
to appropriately compensate for abnormalities in the other. In this work, however, we explore
this argument by computationally adjusting IP3R1 sensitivity to IP3 in SCA15/16 (in the
context of reduced IP3R1 levels) to see if interventions of this type can actually restore
normal calcium response indistinguishable from wild type. We also suggest that, in
polyglutamine SCAs with hyperactive IP3R1, experimentally observed downregulation of

IP3R1 and other calcium signaling proteins (but not calcium buffers) could serve to partially
restore normal calcium transients in ataxias.
We test our hypotheses in a novel version of a recently developed computational model that
links biochemistry with electrophysiology [36]. We simulate the application of different
experimentally available peptides that resemble various portions of the C-terminal of IP3R1,
in order to model competitive inhibition of the binding of mutant ataxin proteins.
Improvements are made to the model, resulting in an ability to look at changes in membrane
potential in response to IP3R1-mediated calcium release or supralinear calcium transients.
We show that adjusting IP3R1 sensitivity to IP3, using peptides resembling the C-terminal of
IP3R1, could potentially stabilize calcium, without altering fine-tuning of supralinear calcium
release required for normal Purkinje neuron function and long term-depression. The model
also demonstrates that decreased levels of IP3R1 and various other calcium signaling proteins
(except for calcium buffers) experimentally observed in SCA1 mice may partially
compensate for the IP3R1 supersensitivity suggested by Liu et al. [10]. Finally, we link
IP3R1 activity with the influence of calcium on membrane electrophysiology. Results from
our study may provide further insight into the roles that abundance and sensitivity of the
calcium channel IP3R1 play in cerebellar function and coincident detection at IP3R1. Results
may also provide a foundation for future studies on SCA1, SCA2, SCA3, SCA15, SCA16,
and other IP3R1-associated ataxias, which all involve aberrant calcium signaling.

Methods
Merged biochemical and electrophysiological modeling
Our analysis of IP3 and calcium dynamics in SCA Purkinje neurons is based on several
computational studies of normal physiology from our lab [32,35,36]; these will be briefly
described.
The cerebellar Purkinje neuron geometry is complex. In order to combine detailed
biochemistry with electrophysiology in tractable Virtual Cell models (VCell;
http://www.vcell.org) [37-41], we developed a geometry reduction algorithm preserved path
reduction or PPR [36]. This algorithm simplifies the Purkinje neuron geometry to just the
essential dendritic segments and branches in a path between a prototypical dendritic spine
and the soma, while maintaining the dynamic electrical features of the full geometry in these
respective compartments. The resulting model has only 17 compartments and allows us to
readily couple the biochemistry in the spine compartment with the electrophysiology of the
entire system. Reference [36] provides full details of the algorithm and the resultant
geometry.
The baseline VCell model for normal physiology of the system was also previously published
by our laboratory [35]. This compartmental model focused on IP3R1-mediated calcium
signaling in the Purkinje cell, taking into account the increased abundance and decreased
sensitivity of the Purkinje cell IP3R1 relative to other cell types. The input to the system is
provided as a train of IP3 pulses (representing IP3 production from multiple parallel fiber
stimuli) with variable parameters that control the number, amplitude and duration of the IP3
pulses. In addition, the model included influx of calcium representing the opening of voltagegated calcium channels when the Purkinje neuron is stimulated by a climbing fiber. It
therefore allowed the study of coincident activation of the Purkinje spine by multiple parallel

fibers and a single climbing fiber. The model also included the downstream effects leading to
IP3R1-mediated calcium release, as well as calcium buffering and SERCA, which resides on
the sER. All of the spine cytosol species are free to diffuse through the spine neck into the
adjacent dendrite. IP3 also diffuses in the cytosol to bind its calcium channel-coupled
receptor on the sER membrane. Calcium is released from sER stores into the cytoplasm and
also co-activates IP3R1, as well as binds to various buffers. Some of this calcium is also
pumped back into the sER by SERCA. The model definition in VCell includes specifying
reactions, membrane transport mechanisms, stoichiometry, and kinetic rate expressions that
correspond with these processes.
We subsequently created a 3D spatial model that explored [42] the membrane signaling
mechanisms upstream of IP3R. We distinguished between candidate sources of sufficient
phosphatidylinositol-4,5-bisphosphate (PIP2) in the spine for the production of requisite IP3.
Local PIP2 sequestration provided an efficient means of fine-tuning coincident activation of
parallel fiber and climbing fiber stimuli in cerebellar Purkinje neuron spines. The results
reported in this study concluded that local high PIP2 achieved through a sequestration
mechanism could provide sufficient IP3 for supralinear calcium release.
We used optimized parameters [42] to study physiological effects of varying IP3R1
sensitivity and abundance with a physiologically appropriate IP3 signal amplitude and
duration. To manipulate IP3R1 abundance and sensitivity, we adjusted the parameters Jmax
and dIP3, respectively, in our comprehensive model (see a table of parameters in [42]). Small
Jmax values represent reduced IP3R1 abundance. The default value is from Hernjak et al.
[35], and is 10x larger than the IP3R1 determined for neuroblastoma cells, to account for the
increased levels of IP3R1 in Purkinje neurons. The dIP3 parameter represents the dissociation
constant of IP3 from IP3R1, so that high dIP3 values in our model represent low affinity of
IP3R for IP3. We use the apparent affinity of IP3R1 for IP3 as a measure of sensitivity, as in
the experimental study by Tang et al. [43]. Manipulation of these IP3R1parameters was done
in the context of a train of 4 parallel fiber (PF) stimuli followed by a single climbing fiber
(CF) stimulus, following the optimal protocol designed by Wang et al. [44]. This allowed us
to examine the effects of IP3R1 insufficiency and supersensitivity in the context of Purkinje
spine stimulation patterns similar to those in published experimental studies [35,42,44-46].
We investigate the pathophysiology of various SCAs, as well as the influence of IP3R1mediated calcium release on the activity of voltage-gated KCa channels, and thus on
membrane potential. We also combine essential features of the spatial and compartmental
models to create a 3D model of the spine. We use this model to probe the significance of
Homer (associated with the postsynaptic density) physically linking mGluR to IP3R1. The
resulting multicompartmental and 3D spatial Virtual Cell models can be accessed in the
public domain at http://www.vcell.org under the shared username Brown. The models are:
1.
2.
3.
4.
5.
6.

“Brown et al. 2011 Analysis of SCA15-SCA16 with IC4 Peptide Application”,
“Brown et al. 2011 SCA1 Compensation Analysis”,
“Brown et al. 2011 Analysis of SCA1-SCA2-SCA3 with IC-G2736X Peptide”,
“Brown et al. 2011 Purkinje Biochem-Electrophysiol SCA”,
“Brown et al. 2011 Purkinje 3D Spine – Spinocerebellar Ataxia study”, and
“Brown et al. 2011 Combined Purkinje - Several Spines - Current Injection”.

Adapting the PPR Model to the SCA Model
In order to investigate how biochemical signaling at the spine could affect electrophysiology,
we needed to allow calcium release to influence the voltage-gated KCa channels. In the PPR
model, KCa channels were only influenced by calcium influx into a phenomenological
submembrane shell. This allowed for very high transient concentrations of calcium (500 μM),
as well as a high concentration of resting calcium (~ 4 μM) near the inner surface of the
plasma membrane. Since such a high amount of basal calcium is not physiologically observed
or observable (in the absence of Purkinje neuron stimulation by nerve endings from
regulatory cells) and since calcium concentration beyond the submembrane shell was not
explicitly considered in the PPR model, we felt it was important to model calcium less
phenomenologically. Therefore, in this work, we removed submembrane shell calcium from
the model only in the spine and the adjacent dendrite, where calcium signaling biochemistry
is modeled explicitly. The adjacent dendrite was adjusted in tandem with the spine, because
calcium and other molecules involved in biochemical processes are allowed to diffuse freely
between the spine and the adjacent dendrite, restricted only by the geometry of the spine
neck. In a previous study, Hernjak et al. [35] used a one-dimensional model to determine a
dendritic distance, 28 μm from a stimulated spine, at which biochemical concentrations
remained at steady state during synaptic activity. The model therefore assumes that there is
no net molecular flow between compartments, except for the adjacent dendrite (given a
length of 28 μm) and the spine.
In other compartments, calcium influx feeds only into submembrane shell calcium. In the
spine and adjacent dendrite, calcium influx is allowed to directly alter concentration of
calcium involved in biochemical signaling; we term this calcium ‘global calcium’. The
concept of the submembrane shell in electrophysiological models [47-49] assumes a
characteristic relaxation time of 2 ms. This relaxation time represents the time it could take
for submembrane shell calcium to relax to the ‘global calcium’ steady state, 40nM in the
model. The submembrane shell relaxation time conceptually encompasses: (i) diffusion from
beneath the membrane into the rest of the compartment, for example, the spine head, (ii)
diffusion into adjacent compartments, for example, from the spine to the adjacent dendrite,
(iii) buffering by calcium binding proteins, for example, calbindin and parvalbumin, (iv)
uptake into the smooth endoplasmic reticulum by SERCA, and (v) extrusion through the
plasma membrane by the Na-Ca exchanger. In addition, calcium extrusion from the cell by
the plasma membrane Ca-ATPase (PMCA, calcium pump) is modeled explicitly as a
Michaelis-Menten expression.
In order to properly replace submembrane shell calcium with global calcium in the spine and
the adjacent dendrite, (i) – (v) are all modeled explicitly. The model by Hernjak et al. [35]
assumed instantaneous diffusion in the spine, and included diffusion between the spine and
adjacent dendrite. It also included explicit buffering by calbindin and parvalbumin, in
addition to calcium uptake by SERCA. That model did not include calcium extrusion from
the spine or adjacent dendrite. Here, we add in calcium efflux by including the MichaelisMenten Ca-ATPase from the Purkinje neuron electrophysiology models [48,49] and a Na-Ca
exchanger from a study on cerebellar granule cells [50](a similar Na-Ca exchanger in a
Purkinje neuron model was not available). The Na-Ca exchanger is not electrogenic and
simply provides an additional means of calcium extrusion; its kinetics are unchanged in our
model. The total concentration of the Ca-ATPase is increased to allow for calcium efflux
appropriate for maintaining a physiological steady state calcium concentration in the Purkinje
neuron spine. The kinetics for the voltage-gated calcium-activated potassium channels were

adjusted to be influenced by global calcium. This reflects results from experimental studies
which suggest that BK channels can be activated by global calcium concentrations less than
10 μM [51].

The ICpeptide study
The Bezprozvanny lab found that Protein Phosphatase 1 alpha (PP1α) dephosphorylation of
IP3R is largely dependent on PP1α binding the very tip of the C-terminal of IP3R1, and that
IP3R1 dephosphorylation (increased IP3R1-PP1α binding) decreased the receptor’s
sensitivity to IP3 [21,43]. Binding of PP1α to the tip of the endogenous IP3R1 C-terminal and
to peptides that resemble the C-terminal of IP3R1 (Figure 2) (here termed ICpeptides, e.g.,
GST-tagged IC4 in Figure 1a) was added to the model at the ER membrane and in the
cytosol, respectively, with mass action kinetics and a stoichiometry of 1. For example:
Figure 2 Schematic for PP1α binding endogenous IP3R1 and a peptide resembling the
C-terminal of IP3R1 (IC4). This corresponds to the ICpeptide study described in the
Methods section
K f _ IC 4 * PP1 * IC 4  K r _ IC 4 * IC 4 _ PP1

(1)

where Kf_IC4 and Kr_IC4 are the forward and reverse rate constants, respectively, for PP1α
binding the exogenous peptide IC4, and IC4_PP1α represents PP1α bound to the IC4 peptide;
K f _ IP3 R1 _ Ct * PP1 * IP 3R1 _ Ct  K r _ IP3 R1 _ Ct * IP 3R1  Ct _ PP1

(2)

where Kf_IP3R1_Ct and Kr_IP3R1_Ct represent the forward and reverse rate constants for PP1α
binding the endogenous tip of the IP3R1 C-terminal, and IP3R1_Ct_PP1 represents PP1α
bound to IP3R1 at the smooth ER (sER). Rate constants are provided in Table 2. It was
assumed that PP1α bound the ICpeptides and the endogenous IP3R1 with the same affinity.
Table 2 Parameters for new features added to model
Model Parameter
Kf-IC4
Kr-IC4
Kf-IP3R1-Ct
Kr-IP3R1-Ct
Kf-mutant-IC4
Kr-mutant-IC4
Kf-mutant-IP3R1-Ct
Kr-mutant-IP3R1-Ct
mAtaxin_init
PP1α_init
IP3R1-Ct_init
IC4_init
IC-G2736X_init
IC10_init

Value
0.001 uM-1.s-1
0.0005 s-1
10 uM-1.s-1
0.0005 s-1
20 uM-1.s-1
0.0005 s-1
20 uM-1.s-1
0.0005 s-1
variable
1 uM
1 uM
2 uM
2 uM
variable

Comment
Forward rate of IC4 binding PP1α
Reverse rate of IC4 binding PP1α
Forward rate of IP3R1 C-terminal binding PP1α
Reverse rate of IP3R1 C-terminal binding PP1α
Forward rate of IC4 binding mAtaxin
Reverse rate of IC4 binding mAtaxin
Forward rate of IP3R1 C-terminal binding mAtaxin
Reverse rate of IP3R1 C-terminal binding mAtaxin
Mutant Ataxin PolyQ Protein
Directly binds tip of IP3R1 C-terminal
Tip of IP3R1 C-terminal
Competitively inhibits PP1α binding
Associates with polyQ region
Competitively inhibits polyQ binding

Reference
---------[43]
-[43]
[52]
[53]

The C-terminal of IP3R1 can also bind mutant Ataxin. The affinity of the IP3R1 C-terminal
tip was taken to be greater for the mutant protein than for PP1α. This was done to incorporate
two phenomena into the binding reaction. First, planar lipid bilayer reconstitution
experiments from Chen et al. and Liu et al. [6,10] suggest that direct association of the
mutant ataxin protein with the C terminal of IP3R1 leads to supersensitivity of the receptor.
Second, the binding domain of the mutant protein [52] on IP3R1 overlaps the PP1α binding
motif [52] on IP3R1. Mutant protein binding IP3R1 in situ (as in cerebellar slices from mouse
models that can be used to test simulation predictions; see Discussion) may decrease PP1α
interaction with the receptor. These two factors are effectively modeled by assigning a larger
affinity for mutant protein binding to IP3R1 than PP1a binding the receptor. Affinities were
captured by the rate constants, all available in Table 2.

Results
Two main categories of ataxias in humans and mouse models are considered in this study:
those with reduced IP3R1 and those with supersensitive IP3R1 (Table 1). However, some
ataxias involve both phenomena, adding a layer of complexity. Further, a common
component of all these ataxias is abnormal calcium metabolism.

SCA15/16: pathophysiology of IP3R1 insufficiency
In ataxias with reduced IP3R1, e.g., SCA15/16, receptor levels appear to be decreased by
varying amounts, even in conditions of heterozygous gene deletion [3,4,14-16,20]. We
captured this variability in our model by adjusting the abundance parameter Jmax to decrease
IP3R1 levels to 50%, 40%, 30%, 25%, and 10% of the original value. Figure 3a shows the
supralinear calcium response with simulated wild type IP3R1 levels (labeled as ‘Original
IP3R1 density’) when the Purkinje neuron spine is stimulated by a single climbing fiber at
0.15 s (labeled as ‘Ca2+ influx only’), by 4 pulses from a single parallel fiber at 0.1 s (labeled
as ‘Ca2 release only’), or by coincident stimulation by 4 pulses from a parallel fiber at 0.1 s
and a climbing fiber at 0.15 s. The simulation uses Magnesium Green as the calcium
indicator (Kd = 19 μm) that fluoresces more brightly when bound to calcium [35,44]. The
figure indicates that the coincident calcium transient is greater than the sum of the individual
calcium transients from stimulation of only the climbing fiber or only the parallel fiber
[35,42,54]; in our simulations, calcium release alone produces a barely perceptible increase in
free Ca2+, but when it occurs together with calcium influx, the free Ca2+ increase more than
doubles compared to influx alone. The figure also shows that halving the density of IP3R1 (as
in heterozygous mouse models and individuals) severely reduces supralinear calcium release.
Thus, the model can be used to investigate the heterozygous human ataxia SCA15/16.
Figure 3 Increasing IP3R1 sensitivity to IP3 can restore normal calcium response in the
context of reduced IP3R1 levels (a model of SCA15/16). a, Coincident calcium release
(from 4 parallel fiber stimuli and a single climbing fiber stimulus) with IP3R1 levels
decreased to 50% and 10%. b, Wild type levels of supralinear calcium release can be
regained in IP3R1 insufficiency by augmenting IP3R1 sensitivity to activation by IP3, using
IC4 at a concentration that gives a 1.7-fold increase in IP3R1 sensitivity to IP3. This fold
increase in sensitivity is within an experimentally observed range (2-fold) [55]. Fine-tuning
of coincidence detection [42] is preserved

Application of ICpeptide to adjust sensitivity in SCA15/16
Modeling results from Hernjak et al. [35] showed that increasing the sensitivity of the IP3R1
by a factor of 10 did not compensate for a decreased the level of IP3R1 to 10% of the wild
type value. They argued that the normally low sensitivity of IP3R1 to IP3 was required to
assure that calcium release is confined to the activated dendritic spine while the normally
high level of IP3R assures robust calcium release despite the low sensitivity. This result is
consistent with the finding in Figure 3a, which shows that the calcium transient with 10%
IP3R1 abundance is almost entirely due to calcium influx through voltage-gated calcium
channels. Very little of the calcium transient is due to calcium release from the ER, through
IP3R. It allows us to suggest that in Purkinje cells, with have much lower sensitivity of IP3R
to IP3 than in other cell types, decreasing receptor density to 10% of the wild type levels
(which amounts to replacing Purkinje neuron IP3R with levels found in other cell types) is as
good as having no IP3R at all. Figure 4 shows that increasing sensitivity in the wild type
context (by adding mutant Ataxin-2 to the model with normal IP3R levels) disrupts the IP3
response [35]. However, in the context of decreased Purkinje IP3R abundance, augmented
sensitivity (whether comparable to other cell types or greater) could potentially restore
normal IP3 response if the IP3R1 is not lowered as drastically as the factor of 10 used in the
Hernjak [35,54] model.
Figure 4 Simulated application of another ICpeptide in a model of SCA1/2/3 can
restore normal calcium release. Hyperactive calcium release in the presence of mutant
Ataxin can be overcome by application of IC-G2736X, which resembles the polyglutamine
binding domain in the C-terminal of IP3R1, and was developed by Tang et al. [52]. Note that
the dashed light grey line (representing restoration of normal calcium release by application
of ICpeptide in the context of a mutant Ataxin model) directly superimposes on the solid
black line (which represents wild type)
To assess this, we simulated an additional system (see Table 2) that has been shown
experimentally to regulate IP3R1 sensitivity: the phosphorylation state of IP3R1. Tang et al.
discovered that dephosphorylation of wild type IP3R1 by PP1α profoundly reduced the
receptor’s sensitivity to IP3 and decreased IP3R1-mediated calcium release [43]. Indirect
binding occurs through AKAP, an adaptor protein that links IP3R1 to both PKA and PP1αpha
by binding to the LIZ domain in IP3R1 (see Figure 1a). Tu et al. showed that most
association of PP1α, the major dephosphorylator of IP3R1, to the receptor occurs via direct
binding at the C-terminal of IP3R1 [21] (see Figure 1a). Tang et al. created GST-IC4, a
competitive peptide that resembles the tip of the C-terminal of IP3R1 (36 aa, Q2714-A2749)
[43](Table 3). This peptide binds PP1α, preventing its direct association to the C-terminal of
IP3R1 (see Figure 1a). They found that dephosphorylation of IP3R1 could be reduced by
more than twofold by administering GST-IC4. In the model, we simulated treating Purkinje
neurons of SCA15/16 mice with GST-IC4 to see if the resulting increase in IP3R1 sensitivity
to IP3, could augment IP3R1-mediated calcium release. Figure 3b shows that as IC4
increases, the resulting decreased association of PP1α with IP3R1 increases the sensitivity of
the receptor for IP3 and restores normal calcium transients. In the figure, a 1.7-fold increase
in IP3R1 sensitivity corresponds to 1.85uM of IC4 needed to restore normal calcium response
when IP3R1 levels are decreased by 50%. This suggests that an experimental study of GSTIC4 treatment in mouse models of SCA15/16 could show normalized IP3 response with a
fold increase in sensitivity already demonstrated by Tang et al. in in vitro studies [43].
However, as levels of IP3R1 go lower and lower, the fold increase in sensitivity needed to
restore normalcy increases nonlinearly (data not shown). In the model, IP3R1 levels could be

decreased only as far as to 25% and still be able to restore normal calcium with a fold
increase in sensitivity that is experimentally attainable.
Table 3 Suggested use of ICpeptides relevant to this study
ICpeptide
IC4

Base pairs

Minimal binding
region of target
Q2714-A2749
R2731-G2736

IC-G2736X D2590-G2736

IC10

F2627-A2749

F2627-G2736

F2627-G2736

Use suggested by this study

Reference

in vivo competitive inhibition of PP1α
with reduced levels of IP3R1
in vitro/vivo competitive inhibition of
mutant Ataxin
with supersensitive IP3R1
possible alternative to IC-G2726X

(Tang et al., 2003b,
Tu et al., 2004)
(Tang et al., 2009)

(Tang et al., 2009)

The simulations were repeated with the climbing fiber stimulus applied 150 ms after the start
of the train of the PF stimuli, unlike the previous results that have a timing difference of 50
ms. A 150 ms timing between the CF and PF stimuli falls outside the optimal time window
suggested by both experiments [44,56] and modeling [42]. Figure 3b shows that with this 150
ms time difference, supralinear calcium release is lost in the wild type case, as well as in the
heterozygous case. This suggests that restoration of normal calcium release in the model does
not alter fine-tuning of coincidence detection suggested by Brown et al. [42]. Thus,
increasing IP3R1 sensitivity could be explored as a therapeutic tactic in SCA15/16 mouse
models, e.g. IP3R1delta18/delta18 or IP3R1+/− mice.

SCA2: application of ICpeptide in ataxias with pathologically increased
sensitivity
Tang et al. also found that the huntingtin binding site on IP3R1 is immediately upstream of
the PP1α-binding motif on the tip of the IP3R1 C-terminal [52]. The predicted minimal
region on IP3R1 for huntingtin polyglutamine repeat binding (F2627-G2736) actually
overlaps a small portion (5 aa) of the minimal PP1-binding motif (R2731-A2749)[52]. The
huntingtin protein binding IP3R1 may therefore physically occlude or partially hinder
binding by PP1αlpha in vivo and in situ. This would reduce PP1αlpha dephosphorylation of
the receptor, leaving it in a hyperphosphorylated and therefore supersensitive state. A similar
mechanism should occur with mutant Ataxins in SCA2 [10] and SCA3 [6] and also SCA1
[8,10,57], given that the mutant Ataxin and huntingtin proteins all have similarly expanded
CAG repeats.
Figure 4 shows that adding 2 μM mutant Ataxin, e.g. mutant Ataxin-2 in SCA2, to the wild
type model triples the increase in simulated fluorescence of the calcium indicator.
Furthermore, the IP3R1 supersensitivity allows calcium concentration to start rising even
before coincidence with calcium influx. In addition, we simulated the application of a
different ICpeptide in our model. This ICpeptide, IC-G2736X (D2590-G2736)(Table 3), was
also created by Tang et al., and encompasses the part of IP3R1 that encodes the minimal
binding region for the expanded polyglutamine repeats in huntingtin, and likely the mutant
ataxin proteins [52]. Further, Tang et al. used a β–galactosidase assay to show that ICG2736X strongly associates with the mutant polyQ huntingtin [52]. In fact, they also used
viral infection to insert IC10 into striatum of ataxic HD mice, and observed consequent
stabilized calcium signaling, as well as neuroprotective effects [53]. In our model, ICG2736X competitively binds the mutant Ataxin protein and blocks mAtaxin from binding
endogenous IP3R1. The normal sensitivity of IP3R1 to activation by IP3 is therefore restored,

and IP3R1 is no longer supersensitive. Figure 4 shows the restoration of normal supralinear
calcium release. This result allows us to predict that experimental application of such an
ICpeptide in cerebellar slices from mice with ataxias associated with supersensitive IP3R1
and increased calcium release may similarly restore normal calcium response. We expect that
various concentrations of ICpeptide could be needed to normalize IP3R1 sensitivity and
consequently calcium release in SCA1, SCA2, or SCA3, based on the degrees to which
IP3R1 sensitivity to IP3 is pathologically increased. This could depend on the concentration
of the mutant protein in the spine, as well as other unknown factors.

SCA1 (& SCA3): compensation versus pathology
Although expression of IP3R1 and other calcium signaling proteins is reduced in SCA3 mice
[7] and in SCA1 mice and humans [9,11], reduced calcium release is not experimentally
observed in either disease. It is therefore not understood what role reduced IP3R1 plays in the
pathology of these polyQ diseases. Figure 3 suggested that in SCA15/16 and other ataxias
with reduced IP3R1 abundance and consequently reduced calcium release, therapeutic
strategies to increase IP3R1 sensitivity to activation by IP3 could restore normal calcium
release. This begs the question of whether, conversely, the downregulation of IP3R1 in
ataxias with supersensitive IP3R1 could partially or wholly restore normal calcium response.
A glimpse into a compensatory effect could lie in examining actual experimentally observed
relative expression levels in SCA1 [9,11], and using those observed levels in the model with
supersensitive IP3R1. This allows the modeling and simulations to be driven by experimental
observations. Accordingly, a 1.8-fold decrease (approximated from Lin et al. and Serra et al.)
[9,11] was simulated in the model for SCA1 pathology.
Figures 4a and 4b show that tuning down IP3R1 decreases the hyperactive supralinear
calcium release to levels closer to wild type. This suggests that experimentally observed
reduced abundance of IP3R1 may partially compensate for supersensitivity in SCA1 mice.
However, other calcium signaling molecules were also downregulated by at least 1.8-fold
[9,11]. To determine the individual effect of the downregulation of some of the molecules,
each molecule was sequentially downregulated. Tuning down SERCA in addition to IP3R1
has no additive effect. Myosin Va (MyoVa) and Homer 3 also are decreased [9,11]. MyoVa
and Homer 3 are thought to potentially (i) guide sER into the spine, and (ii) anchor sER in the
spine, respectively [58,59]. Decreasing sER volume in the spine by 1.8-fold in the ataxia
model reduces the hyperactive calcium release to levels similar to tuning down IP3R1 or
IP3R1 and SERCA. Although the correlation between Homer and MyoVa expression and
sER volume fraction is probably not linear, it is remarkable that reducing the volume fraction
by 1.8-fold gives a result that is close to directly tuning down IP3R1 and SERCA, which
reside on the sER. Given the critical importance of IP3R1 on the sER in normal Purkinje
neuron function, reduced volume fraction of spine sER could contribute to the
pathophysiology of IP3R1-associated ataxia. However, in the context of IP3R1
supersensitivity, Homer and MyoVa downregulation could be compensatory. Finally, tuning
down mGluR (by tuning down pulsatile IP3 production) in addition to SERCA and IP3R1
further decreases hyperactive calcium release, so that the resulting supralinear calcium
release in the ataxic model is even closer to wild type. This is remarkable, suggesting that
mGluR downregulation [9,11] is also compensatory, and additive to IP3R1 downregulation.
Not surprisingly, Figure 5b suggests that the greater the concentration of mutant Ataxin, the
less the compensation achieved by tuning down IP3R1, SERCA, mGluR, and Homer.

Figure 5 Downregulation of IP3R1, SERCA, mGluR, and Homer/MyoVa appears to be
compensatory, but downregulation of calcium buffers may contribute to pathology. a
&c, Supralinear calcium release in wild type and with mutant Ataxin and with each molecule
downregulated cumulatively, assuming supersensitive IP3R1 (a) or normosensitive IP3R1
(c). For the red curve, the calcium buffers PV and CB are downregulated by 30% in addition
to at least a 1.8-fold decrease in concentration for IP3R1, SERCA, and mGluR. b&d, The
compensation trend plotted for various potential concentrations of mAtaxin, showing the
inverse relationship between the extent of compensation and the relative concentration of
mAtaxin in the spine, assuming supersensitive IP3R1 (b) or normosensitive IP3R1 (d)
Expression of calcium-binding proteins, parvalbumin and calbindin, are also experimentally
observed to be reduced [9,11]. It is not known whether this contributes to pathology or
compensation. Calbindin knockout mice crossed with SCA1 mice worsens the phenotype [9].
This suggests that low levels of these buffer proteins could accelerate pathology. It is possible
that normal or high levels of buffer proteins may help to maintain homeostasis in the
presence of supersensitive IP3R1 early on in the SCA1 disease, then, when their expression is
reduced, homeostasis is lost. Modeling results support this suggestion. Tuning down the
calcium buffers parvalbumin and calbindin in the model makes supralinear calcium more
robust than with down regulation of IP3R1, mGluR and SERCA alone (Figure 5a,b).
Accordingly, the downward trend in the peak concentration of calcium is reversed with down
regulation of calcium buffers. This is consistent with studies in Purkinje cells from
parvalbumin and calbindin knockout mice that are ataxic [60,61], where peak amplitudes of
calcium transients evoked by climbing fiber stimulation were double those in wild type mice
[62]. Notably, it has been suggested that because reduced expression of buffer proteins is
observed in SCA1 mice before onset of symptoms, the timing of buffer protein
downregulation may help determine the onset of symptoms [63,64].
Notably, Liu et al. report that mutant SCA1 pathologically associates with IP3R1 [10], as do
SCA2 and SCA3 [6,10], suggesting a common supersensitive IP3R1 pathology, but they do
not actually measure or report changes in IP3R1 sensitivity. Thus, we thought it was
important to consider changes in calcium resulting from signaling protein downregulation,
even if hyperactive IP3R1 is not assumed. Figures 5c and 5d illustrate that calcium responses
resulting from IP3R1 and other calcium signaling protein downregulation, but with normal
IP3R1 sensitivity, are less robust than wild type. This indicates that downregulation of these
proteins in the absence IP3R1 supersensitivity does not appear consistent with the elevated
calcium response relative to wild type, as observed in SCA1 mice [8]. The model therefore
supports the hypothesis of IP3R1 supersensitivity in SCA1.

Influence of calcium on voltage-gated calcium-activated potassium channels
To better understand the interplay between calcium signaling and electrophysiology, we
investigated the relationships between calcium influx, IP3R1-induced calcium release, and
the voltage-gated calcium-activated potassium (KCa) channels. Our model includes the BK
channel (‘big’ conductance calcium-activated voltage-gated potassium channel) and IK
(intermediate conductance calcium-activated voltage-gated potassium channel) channels.
Since more is known about the BK channels, we focused our study design and interpretation
on these channels (see schematic in Figure 1b). The BK channel in the cerebellum is thought
to contribute to repolarization of membrane potential transients in the dendrites, particularly
calcium spikes (transient depolarization of membrane potential in spines and dendrites)
resulting from the opening of voltage-dependent calcium channels in the dendrites [49]. In

addition, experimental results by Sausbier et al. using ataxic BK knockout mice suggest that
these channels are also important for the afterhyperpolarization of action potentials at the
soma [65]. BK channels contribute to precision timing, and are thus important for normal
firing of the cerebellar Purkinje neurons [65-70].
IP3R1 interacts closely with the BK channel, in glioma cells [71]. The BK channels seem to
be in lipid rafts in the plasma membrane apposed to the sER. It is thought that in other cell
types, including some neurons, the BK channels may form physical complexes with various
plasma membrane calcium channels, bringing them within a few nanometers of the calcium
channel pores [72]. We suspect that in the cerebellar Purkinje neuron spines, BK activity is
also closely linked with the IP3R1-mediated calcium release. This idea is supported by direct
activation of the BK channel by IP3R1-mediated calcium release in pyramidal neurons [73]
and cereberal artery smooth muscle cells [74]. We therefore set out to investigate possible
activation of BK channels (and IK channels) by IP3R1-mediated calcium release.
In the model, we allowed calcium released from the sER in eleven spines to activate the
voltage-gated KCa channels. A group of eleven spines represents a small portion of a dendrite
branchlet. (The Purkinje neuron has ~ 14 spines per μm2 (Harris and Stevens, 1988)). Figure
6a shows that a 20 nA current injected at the soma for 400 ms gives a single sodium action
potential spike, followed by a gradual incline. When calcium influx due to CF stimulation is
applied 40 ms after the start of the current injection, an identical result is obtained (data not
shown). When calcium release due to PF stimulation is applied 20 ms before the start of the
current injection, a single sodium action potential spike is obtained, followed by the gradual
incline, but then terminates with a short action potential train (Figure 6b). These action
potential oscillations are similar to tonic firing oscillations observed experimentally [65]. An
identical result is obtained when calcium influx is also added in 40 ms after the start of
current injection. Thus in contrast to Figures 2 and 3, where calcium release is stimulated in
only one spine, the transient calcium influx may not significantly enhance the overall effect
of calcium release in 11 spines. This point is corroborated by examination of the
corresponding calcium transients shown in Figure 6c. With PF stimuli only, in the absence of
current injection, the Ca transient is minimal. With current injection at the soma, in the
absence of biochemical signaling, there is a significant calcium transient at the level of the
spines, corresponding to that first membrane potential spike. During that spike, sodium
channels open at the soma, and calcium channels open throughout the dendrite. That allows
calcium to rush into the cell. The calcium concentration then gradually rises, corresponding
to the membrane potential incline. With PF stimuli preceding current injection onset by 20
ms, IP3 is already bound to IP3R1 when calcium rushes in through voltage-gated channels in
the spines (in response to the depolarization of the membrane during current injection). This
calcium also binds to IP3R1 on the sER. Thus, we have IP3 and calcium bound to IP3R1,
yielding coincident activation of the receptor. In this case, coincidence detection is not of PF
and CF stimuli, but of PF stimuli and current injection. IP3R1 can therefore serve as a
coincidence detector for any activation of the Purkinje neuron that leads to changes in
intracellular calcium concentration and increases in IP3 concentration. The figure shows that
the resulting calcium transient is supralinear. With the CF stimuli only, a sharp calcium
transient is obtained. When the CF stimulus is combined with current injection, the calcium
transient is simply additive. This is because neither CF stimulus nor current injection
provides IP3, which is necessary for coincidence detection at IP3R1. The corresponding
modulation in the conductance of the BK channels is shown in Figure 6d. The figure
indicates that BK channel conductance begins to rise almost immediately after either calcium
release or calcium influx or both. Not surprisingly, the supralinear calcium transients give the

biggest increases in conductance of the BK channels. The influence of the calcium transients
on BK channels alters the membrane potential of the Purkinje neuron. The figure shows that
with the calcium release from PF stimulus only, termination of the current injection results in
a short train of action potentials. As with the membrane potential in Figure 6a, this spike does
not occur in the absence of the PF stimulus. With supralinear calcium release activating BK
channels, this also gives a termination spike that is identical to that obtained with calcium
release only. CF stimulus alone does not alter the membrane potential.
Figure 6 Membrane potential response to a 400 ms current injection at the soma is
altered by biochemical calcium transients in eleven adjacent spines. a, Membrane
potential response at the soma in response to a 400 ms 2 nA depolarizing current injection at
the soma. b, Action potentials at the soma in response to a depolarizing current injection at
the soma superimposed with PF-induced calcium release (20 ms before the start of the current
injection). c, Corresponding calcium transients at the spine with an inset magnifying the
lower amplitude responses. d, Corresponding changes in BK channel conductance at the
spine. Note that in c and d, the solid red and green lines directly superimpose beyond 0.3 s
In Figure 7, current injection commences significantly before both the PF and CF stimuli: PF
stimulus occurs 160 ms after current injection, but still occurs 60 ms (within the
experimentally observed time window [56]) before the CF stimulus. In addition, the current
injection now lasts for 800 ms, as opposed to 400 ms in Figure 6. Figure 7a shows that in the
presence of a prolonged current injection, a train of action potentials can be induced in the
absence of any calcium increase. Consistent with Figure 6, with PF stimulus only, action
potential spikes at the soma appear earlier (Figure 7b, top panel) than in the absence of the
resulting biochemical calcium transient (Figure 7a, top panel). The bottom panels in Figures
6a and 6b show the corresponding calcium potential spikes at the spine, with similar results.
These calcium spikes occur once a depolarization threshold is reached in the dendrites and
spines, in response to high frequency repetitive firing of the Purkinje neuron (corresponding
to high amplitude current injection) [49]. The resulting change in membrane potential in the
dendrites and the spines propagates to and is reflected at the soma as the transient plateaus
that occur in the midst of the sodium spikes. The resulting calcium transients are similar to
those in Figure 6, in that superposition of parallel fiber stimulus and current injection gives
supralinear calcium release, and further superposition with CF stimulus gives a calcium
transient that is additive (Figure 7e). Also similarly, the supralinear calcium transient from
calcium release and current injection leads to earlier calcium signal oscillations than in the
absence of the biochemical calcium signal (Figure 7e). Interestingly, the calcium obtained
from CF stimulus superimposed with current injection results in earlier membrane potential
spiking (Figure 7c) than the supralinear calcium release from PF stimulus and current
injection superposition (Figure 7b). Virtually identical results are obtained with coincident
CF and PF activation superimposed with current injection (Figure 7d) as in Figure 7c. The
calcium release portion of the calcium signal falls off more quickly upon superposition of CF
and PF stimuli than supralinear calcium release from PF stimulus alone (Figure 7e). This can
be attributed to the IP3R1 bell-shaped curve response to calcium concentration [75], where
the calcium concentration rises sufficiently during combine Ca2+ influx and current injection
to significantly populate the inhibited state of IP3R1. Since the calcium response falls off
during this sustained potion of the overall Ca2+ signal (Figure 7e), the BK conductance also
falls off (Figure 7f), thus affecting the membrane potential. Figure 7 suggests that the overall
contour of the calcium signal and the resulting KCa conductances changes may underlie the
effect of calcium on membrane excitability.

Figure 7 The onset of action potential oscillations is altered by calcium transients in
eleven adjacent spines, with an 800 ms current injection and a different timing sequence
between PF and CF stimuli. a, Membrane potential oscillations at the soma (top panel) and
the spine (bottom panel) in response to a 800 ms depolarizing current injection at the soma
(no calcium influx or release). b, Membrane potential oscillations at the soma (top panel) and
at the spine (bottom panel) in response to a depolarizing current injection at the soma
superimposed with calcium release only (160 ms after the start of the current injection). c,
Membrane potential oscillations at the soma in response to a depolarizing current injection at
the soma superimposed with calcium influx only (220 ms after the start of the current
injection). d, Membrane potential oscillations at the soma in response to a depolarizing
current injection at the soma superimposed with both calcium release and influx. e,
Corresponding calcium transients at the spine. f, Corresponding changes in BK channel
conductance
Taken together, these results suggest that in Purkinje neurons, coincident activation of the
Purkinje spine by current injection at the soma and IP3R1-mediated calcium release with or
without concurrent CF stimulus can alter membrane excitability. The results indicate that KCa
activity increased by calcium release led to earlier action potential spikes than in the absence
of biochemically induced calcium transients. This is reminiscent of a study by Sausbier et al.
[65], in which control mice with wild type levels of BK activation showed more spontaneous
discharge relative to ataxic BK−/− mice. This is presumably due to another important result
from that study: BK activity generates afterhyperpolarization of sodium (action potential)
spikes. Thus, augmented BK channel activity polarizes the plasma membrane and increases
excitability by more quickly resetting the sodium channels.
Computational models that combine the cell biology of calcium signaling with membrane
electrophysiology involving calcium channels and calcium-activated ion channels can reveal
emergent properties that are not observed in models of purely biochemical or purely
electrophysiological models. The models that are presented in this work can be useful for
studying these emergent properties in normal physiological Purkinje neurons, as well as in
ataxia. Future studies can be developed to study spontaneous Purkinje neuron firing rate or
precision of spike timing and interspike intervals in various classes of ataxias with mutations
in genes that code for calcium channels [9,76-78] and potassium channels [65,79], as well as
IP3R1 or related proteins (including SCA1, SCA2, SCA3, SCA15/16) [3,4,6,7,9-16].

Discussion
We determined that the Virtual Cell modeling environment [36] can be used to study cellular
dynamics associated with disease states, particularly spinocerebellar ataxias with altered
IP3R1 abundance or sensitivity or both. We modified a quantitative multicompartmental
model recently developed in Virtual Cell to investigate the coupling of detailed biochemistry
of IP3 and calcium signaling with membrane potential. Results show that computational
modeling allows us to simulate the behavior of calcium dynamics and membrane potentials in
neurons at the level of the spine and of the soma, in response to various stimuli. Our models
include a myriad of ion channels and molecules important for normal Purkinje neuron
function. They merge features of IP3 production, phosphoinositide and calcium signaling
with conceptual representations of parallel fiber and climbing fiber stimulation, local PIP2
synthesis and sequestration, PIP2 hydrolysis, calcium influx, coincident detection at IP3R1,
modulation of IP3R1 abundance and sensitivity, IP3R1-mediated supralinear calcium release,

and components of membrane electrophysiology into comprehensive models that can have
compartmental and spatial counterparts.
Results suggest that ICpeptides may be used to modulate calcium release in various IP3R1associated ataxias (ataxias in which IP3R1 is less abundant, e.g., SCA15/SCA16 as well as
SCA1 and SCA3, or more sensitive than in wild type mice or unaffected individuals, e.g.,
SCA2 and SCA3 and likely SCA1). Simulations predict that pathophysiology associated with
decreases in IP3R1 abundance can be overcome by adjusting IP3R1 sensitivity to activation
by IP3, and that targeting PP1α can restore normal calcium transients. Various concentrations
of ICpeptide may be needed to increase IP3R1 sensitivity in SCA15/SCA16, based on the
levels of reduced abundance. Similarly, various concentrations of ICpeptide could be needed
to normalize IP3R1 sensitivity and consequently calcium release in SCA1, SCA2, and SCA3,
based on the degrees to which IP3R1 sensitivity to IP3 is pathologically increased (dependent
on the concentration of mutant protein and the relative balance with PP1α).
This project complements results by Hernjak et al. from a study on Purkinje spine calcium
signaling that considered the importance of low sensitivity and high abundance of IP3R1
suggested by experiments [35]. Findings from that study suggested that increasing IP3R1
sensitivity to IP3 could not rescue calcium release in the context of low IP3. However, our
results show that increased sensitivity can restore normal IP3 response if the abundance is not
too low. This provides further insight into the roles that IP3R1 abundance and sensitivity play
in normal cerebellar functioning and coincident detection at IP3R1. IP3R1 abundance and
sensitivity can each function as the primary pathology in IP3R1-associated ataxias or can
serve to partially or wholly compensate the effects of pathology. Other important conclusions
from the study by Hernjak et al. were that the low IP3R1 sensitivity observed in wild type
Purkinje neurons relative to other cell types may be important to restrict biochemical signals
and synaptic plasticity to one spine, and that the high IP3R1 abundance in Purkinje neurons is
important for ensuring generation of a robust calcium signal in an individual spine. The
current study confirms that the balance of IP3R1 abundance and sensitivity is critical for
obtaining robust, but not hyperactive, calcium transients. It is possible that in ataxias with
reduced abundance of IP3R1, some spines will not generate robust calcium signals, while in
ataxias with supersensitive IP3R1, stimulation signals may not be confined to single spines.
This could affect both compartmentalization of biochemical signals, and the influence of the
biochemistry on membrane electrophysiology. Similarly, therapeutically increased IP3R1
sensitivity (by application of an appropriate ICpeptide) could potentially lead to spillover of
calcium into adjacent spines, if sensitivity is not finely tuned. Modeling could thus be useful
for helping to determine the adequate levels of ICpeptide to be administered experimentally.
Experimental observations in SCA1 mice appear to be paradoxical [30] (Table 1). The
expression of various molecules (for example, IP3R1, Homer, and SERCA) involved in
glutamatergic calcium signaling and IP3R1-mediated calcium release is reduced in mice and
humans with SCA1 [9,11]. However, IP3-induced calcium release is hyperactive in SCA1
mice [8]. Insight may be gained by examining the pathology of SCA2 and SCA3. Liu et al.
[10] and Chen et al. [6] found that mutant Ataxin-2 and Ataxin-3, respectively, bind the Cterminal of IP3R1 and increase the receptor’s sensitivity to activation by IP3. This
corresponds to hyperactive IP3-induced calcium release in both SCA2 and SCA3. Above
normal numbers of CAG repeats in SCA1, SCA2, and SCA3 give each respective mutant
ataxin protein a toxic gain of function that disrupts calcium homeostasis in neurons. Thus,
there may be a common mechanism underlying some of the pathology of the three polyQ
ataxias. This mechanism could be binding of the polyQ-expanded protein to the C-terminal of

IP3R1, thereby increasing the receptor’s sensitivity to IP3. This mechanism may be
extendable to a large variety of polyglutamine diseases. In fact, Liu et al. reported that the
mutant Ataxin-1 protein and polyQ-expanded atrophin-1, the protein mutated in
Dentatorubral-pallidoluysian atrophy (DRPLA), both associate with the C-terminal of IP3R1
[10], though IP3R1 supersensitivity has not yet been assessed experimentally in either
disease. Of note, a prominent feature of DRPLA is cerebellar ataxia [80-83].
The pathological gain of function of IP3R1 sensitivity that destabilizes calcium signaling [84]
is also observed in a mouse model of Huntington’s disease (HD), another polyQ disease
[18,52,53,85-87]. Lentiviral and adenoviral infection of affected cultured medial striatal
neurons or in the striatum of the ataxic HD mice themselves with the IC10 peptide lead to
reduced brain atrophy and improved motor coordination, respectively [53]. Perhaps similar
genetic targeting of Purkinje neurons in the cerebellum of existing mouse models with ICG2736X could mitigate the pathology of SCA1, SCA2, and SCA3. This could first be tested
in in situ experiments using cerebellar slices from existing mouse models, in which mutant
ataxin1 binding IP3R1 directly upstream of the PP1αlpha binding site, would be close enough
to preclude binding of PP1αlpha.
Reduced gene expression of IP3R1, Homer/MyoVa, mGluR and other molecules in SCA1
may be due to direct pathology due to the effect of the mutant proteins on transcription [7,9];
it could also be due to the tight regulation of calcium homeostasis in the cerebellar Purkinje
neuron [30]. Lin et al. suggest that reduced gene expression is a part of the pathology [9], but
our model indicates that with exception of the calcium buffer proteins the effect on IP3R1mediated calcium release is partially compensatory. Using the reduced fold expression
observed in SCA1, normal calcium release was restored to varying degrees, depending on
how much mutant Ataxin protein was placed in the model. Reduced expression of several
calcium signaling genes is also observed in some Purkinje neuron subtypes in plasma
membrane calcium ATP-ase (PMCA) knockout mice [20]. This could also have the effect of
partial compensation in that mouse model, since PMCA contributes to expelling calcium
from the Purkinje neuron cytoplasm. ‘Compensatory pathology’ is thus an interesting
characteristic of various ataxias, and provides a level of complexity to the study of these
neurological disorders. Disruption of calcium signaling and homeostasis, whether due to
reduced IP3R1 levels or supersensitive IP3R1, whether in IP3R1-associated ataxias or in
other ataxias, can lead to dysfunction of Purkinje cells, and impaired long-term depression
and synaptic plasticity that are involved in learning and memory.
Calcium homeostasis is critical for normal function of Purkinje neurons and is thought to be
tightly regulated [30]. Downregulation of parvalbumin and calbindin could therefore lead to a
loss of compensation, by destabilizing supralinear calcium release and disrupting any
homeostasis achieved by downregulation of other molecules. Furthermore, it has been
postulated that normal or high concentration of calcium buffer proteins have a protective role
in certain neurons [63]. Vig et al. suspect that the decrease in parvalbumin expression in
Purkinje cells from SCA1 patients may reflect alterations in a regulatory biochemical
pathway that may be important for neuronal survival [63]. Further, our model suggests that
these changes (downregulation of various calcium channels and buffers) alone may not be
sufficient to reproduce elevated calcium response as observed experimentally in SCA1 mice,
without assuming concurrent supersensitive IP3R1.
Purkinje neurons are largely spared in SCA3 [88], while nerve cells in the pons and
substantia nigra are substantially damaged. Chou et al. suggest that although prominent

neuronal loss was not found in the cerebellum, the SCA3 mice displayed pronounced ataxic
symptoms, suggesting that instead of neuronal demise, mutant Ataxin3 causes neuronal
dysfunction and resulting ataxia [7]. While Ataxin1 is found in the nucleus, Ataxin 2 and
Ataxin3 are cytoplasmic proteins, under normal conditions. However, in brains from patients
with SCA3, mutant Ataxin3 accumulates in the nucleus [28,89], as does mutant Ataxin1 [90].
Hence, results from our study of SCA1 could be extended to SCA3 modeling.
Long term feeding of SCA2 and SCA3 mice with dantrolene improved motor coordination
and slowed brain atrophy [6,10]. Dantrolene is thought of as a ‘calcium stabilizer’ [6,10,91]
and has been shown to inhibit the ryanodine receptor (RYR), which is another calcium
channel on the smooth endoplasmic reticulum [92,93]. However, all the targets of dantrolene
are not known [94]. The details of the mechanism of action of dantrolene are incomplete [94],
though it has been proposed as a possible therapeutic drug for SCA2 [10] and SCA3 [6]. The
drug is currently approved to treat malignant hypothermia as a one-time application in
response to adverse reaction due to anesthesia [94-96]. It is also used to reduce muscle
spasticity in patients with neurological incidents or disorders. However, dantrolene leads to
fluid buildup in the lungs, among other adverse effects [94]. Yet, considering the disturbed
neuronal calcium signaling observed in polyQ ataxias, it is likely that inhibiting or
downregulating either or both of the sER intracellular calcium release channels (IP3R1 and
RYR) should attenuate IP3R1-mediated supralinear calcium release into the cytosol and
thereby alleviate SCA2 and SCA3. This is particularly so, since both the RYR and IP3R1
channels increase in function when directly bound by cytosolic calcium. Therefore the
supralinear calcium release cascade initiated by IP3 binding IP3R1 may involve cytosolic
calcium also binding RYR to increase calcium release from the sER. Adding RYR to the
model in the future will facilitate further study of the signaling interactions among RYR,
IP3R1, other calcium channels, and the calcium-activated potassium channels. However, it
should be noted that there is evidence that RYR is localized to the dendritic shaft and is
excluded from spines [97,98]. Yet, there is also evidence that these physically separate
calcium release sites functionally interact [99].
Predictions from our computer model involving SCA15/16 could be compared with novel
experiments in an existing mouse model using GST-IC4 to dissociate PP1α from IP3R1 in
Purkinje neurons in cerebellar slices from ataxic mice. This could restore normal calcium and
membrane potential response in ataxic mice. For such experiments, it would be useful to
select a mouse model that: (i) does not completely knock out IP3R1 expression as in the
IP3R1−/− knockout mice, but has reduced expression of IP3R1 protein, (ii) shows motor
discoordination, (iii) does not possess a mutation in neuronal IP3R1 at the preferred site of
PKA phosphorylation (Ser-1755) [100], and (iv) does not possess an IP3R1 mutation in the
carboxyl terminal PP1α-binding site (2731–2749) [43]. For assessing IP3R1
haploinsufficiency in particular, as found in SCA15 and SCA16 patients [3,12,15,16], it
would also be useful to select a mouse model with a large heterozygous deletion mutation in
IP3R1. The IP3R1 +/− mice [2,5] fulfill all of these desired features. The IP3R1delta18/delta18
mice have also been suggested as a mouse model for SCA15/16 [3]. The ITPR1opt/opt mouse
model (see Figure 1b) shows reduced IP3R1 protein levels on Western blot, but has a
mutation that deletes the preferred PKA phosphorylation site (Ser-1755) [4,100] in neuronal
IP3R1, and therefore violates (iv). Given that a very small region of the gene is deleted and
that it occurs at such an important regulation site, we suspect that IP3R1 is dysregulated in
these mice. As such, we expect that these mice possess cellular pathophysiology resulting
from dysregulation in addition to effects of IP3R1 insufficiency. Consequently, it is yet

unclear whether results from this study will be easily extendable to calcium signaling and
membrane excitability in ITPR1opt/opt mice.
Results from our models suggest that IP3R1-mediated calcium release can activate voltagegated KCa channels and thereby alter membrane excitability in the Purkinje neuron. This can
have implications for ataxias that involve disruption of intracellular calcium homeostasis. It is
possible that pathological alterations in calcium transients result in pathological activation of
BK channels. This could lead to variations in the timing of action potentials and other
electrophysiological events in the Purkinje neuron, which controls modulation of neurons
downstream of the cerebellum.

Conclusions
In summary, we created a series of models incorporating biochemistry and electrophysiology
that unify observations in various SCAs. These models employ several novel concepts and
approaches and provide a framework for the study not only of IP3R1-associated ataxias, but
of various SCAs involving mutations of other molecules in the model, such as potassium
channels [65,79,101,102] and calcium channels [29,76,77,103].
Model results indicate that, in mouse models of various ataxias associated with activity of the
calcium channel IP3R1, ICpeptides may be used to stabilize intracellular calcium
concentration. Further, restoration of normal calcium release in the model does not alter finetuning of coincidence detection suggested by Brown et al. [42]. The hypothesis of IP3R1
supersensitivity in SCA1 is supported by simulation results. Even more, IP3R1
downregulation experimentally observed in SCA1 mice may partially compensate for the
receptor’s supersensitivity. Homer and MyoVa downregulation are further compensatory.
However, downregulation of calcium buffer proteins accelerates pathology. The model
demonstrates that IP3-mediated calcium release in the Purkinje neuron could activate
voltage-gated KCa channels, namely BK and IK, and provides insight into the interplay
between IP3R1 sensitivity and abundance in the function and dysfunction of the Purkinje cell.
Results help to explain experimental findings in mice, and can be used to make predictions
for further experiments, which may ultimately be translated to ataxic individuals with
reduced IP3R1 protein levels or increased sensitivity. IP3R1 abundance and sensitivity are
components involved in calcium signaling, but by no means the only factors involved in the
signaling systems of these SCAs.
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